37,313-share grant to Abeona Therapeutics (ABEO) director Mark Alvino

Rhea-AI Filing Summary

Abeona Therapeutics director Mark Alvino received a grant of 37,313 shares of common stock on January 26, 2026, at a price of $0.00 per share. These are restricted shares that will fully vest on January 26, 2027. Following this award, he beneficially owns 86,065 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alvino Mark

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	86,065	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Mark Alvino	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Mark Alvino?

Abeona Therapeutics reported that director Mark Alvino received 37,313 shares of common stock as an award. The shares were acquired at $0.00 per share and are classified as restricted stock subject to a future vesting date.

When do Mark Alvino’s newly awarded Abeona (ABEO) restricted shares vest?

The 37,313 restricted shares awarded to director Mark Alvino will fully vest on January 26, 2027. Until that date, the stock remains subject to vesting conditions typically tied to continued service on the company’s board.

How many Abeona Therapeutics (ABEO) shares does Mark Alvino own after this Form 4?

Following the reported transaction, director Mark Alvino beneficially owns 86,065 shares of Abeona Therapeutics common stock. These shares are reported as held with direct ownership, reflecting his position after the restricted stock grant on January 26, 2026.

What transaction code was used for Mark Alvino’s Abeona (ABEO) stock award?

The filing uses transaction code "A", indicating an acquisition of securities. In this case, it reflects a grant of 37,313 restricted common shares to director Mark Alvino at an acquisition price of $0.00 per share as compensation.

Is Mark Alvino a director or officer of Abeona Therapeutics (ABEO)?

The filing identifies Mark Alvino as a director of Abeona Therapeutics. He is not reported as an officer or 10% owner in this Form 4, and the form is filed for a single reporting person only.